Monoclonal Antibody-Directed Therapy

doi:10.3390/books978-3-0365-2872-4

Download Url(s)

https://mdpi.com/books/pdfview/book/4899

Contributor(s)

Kayser, Veysel (editor)

Datta-Mannan, Amita (editor)

Language

English

Show full item record

Abstract

The book deals with therapeutic monoclonal antibodies (mAbs) broadly, and relevant topics such as challenges and opportunities, next-generation antibody products, Antibody-Drug-Conjugates (ADC), bispecifics, glycosylation, and T-cell engagers are covered. Each topic has been written by leading groups around the world and the book should be of interest to researchers from both academia and industry.

URI

https://directory.doabooks.org/handle/20.500.12854/78804

Keywords

therapeutic antibody; stability; aggregation; manufacture challenges; formulation; antibodies; site-specific conjugation; bioconjugates; ADC; antibody-drug conjugates; payloads; linkers; nucleic acids; ADME; developability; glycosylation; post-translational modifications; pharmacokinetics; effector functions; antibody-dependent cell-mediated cytotoxicity; complement-dependent cytotoxicity; immunogenicity; pharmacodynamics; glycoengineering; type III secretion system; prophylaxis; antibacterials; antibiotics; HIV/AIDS; co-formulation; high concentration; analytical characterization; antibody (s); T-cell engagers; bispecific antibodies; immunotherapy; oncology; antibody engineering; immunological synapse